VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell M1rNeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2S3XGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTV2MzFOwG0> NEjVcmhUSU6JRWK=
human NCI-H720 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmfuTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF4OEKg{txO MkLOV2FPT0WU
JVM-2 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVyyO5B{UW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> NVLVWY9JW0GQR1XS
human NCI-H69 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;sV2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODl7NEGg{txO MUjTRW5ITVJ?
human BV-173 cell NHnSbmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmLsTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOzh4IN88US=> NVG1Zmh7W0GQR1XS
human KU812 cell NYLxeWFnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF;LcXFKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjR6ODFOwG0> NEXWOotUSU6JRWK=
human DU-145 cell NVztTI5TT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLaVm9qUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2NUW0JO69VQ>? NHLLZlhUSU6JRWK=
KARPAS-45 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGDRWI5KdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUS4NlYh|ryP M3nYZXNCVkeHUh?=
human AGS cell NFziRmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfhb4NmUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjVzIN88US=> MVHTRW5ITVJ?
human MOLT-13 cell NEnxNnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWHXV2VmUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NUDPxE1? NF\1WFdUSU6JRWK=
human NCI-H209 cell M{nl[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LSU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO NHT2SllUSU6JRWK=
human CTV-1 cell NEfmNXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNVXi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPFM5QSEQvF2= NFTjNlRUSU6JRWK=
LU-139 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGG4OG1KdmirYnn0bY9vKG:oIHj1cYFvKEyXLUGzPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTl2M{Wg{txO MYLTRW5ITVJ?
ML-2 cell NWHxc3NIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYPRNnF5UW6qaXLpeIlwdiCxZjDoeY1idiCPTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOjZ4MTFOwG0> NF72d4tUSU6JRWK=
human K5 cell MmfkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnTuTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkK5NVch|ryP Mki3V2FPT0WU
human SBC-1 cell M2rCR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnyyTY5pcWKrdHnvckBw\iCqdX3hckBUSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlM3OiEQvF2= NXPtfZdFW0GQR1XS
human COR-L88 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnHVJhKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|NEig{txO M3vqPHNCVkeHUh?=
human KY821 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkLETY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k3ODNizszN MYHTRW5ITVJ?
human HCC2218 cell M2rBXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jsR2lvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMkKxPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDl5Mkig{txO MVPTRW5ITVJ?
human ECC10 cell NXPiOFR6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3zqWGlvcGmkaYTpc44hd2ZiaIXtZY4hTUOFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY2Ozh7IN88US=> NV7KZpVqW0GQR1XS
human EW-3 cell NFG4bYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1fOfmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOlY3OTFizszN M{XnS3NCVkeHUh?=
human EW-18 cell M4rPS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFG4SI5KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PDZ5OTFOwG0> MkLiV2FPT0WU
human UACC-257 cell NWOxbnNHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2nmXWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz2yOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJyM{K2JO69VQ>? MUXTRW5ITVJ?
human G-361 cell MoLjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDDTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN MYfTRW5ITVJ?
human HMV-II cell NV;xenNET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXO0RpNMUW6qaXLpeIlwdiCxZjDoeY1idiCKTW[tTWkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjd5MUi0JO69VQ>? MmTKV2FPT0WU
human DEL cell M2TpR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnDTY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKwO|A1KM7:TR?= NVrDZZhOW0GQR1XS
human IGROV-1 cell Mm\uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3\FWGlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDNzOEig{txO NEe1VWtUSU6JRWK=
human SK-OV-3 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXi5OJhwUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MU[5O{DPxE1? M{HycnNCVkeHUh?=
human LAMA-84 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFTJO3JKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjdzMki0JO69VQ>? NXnHbotlW0GQR1XS
human NCI-H510A cell NXXkbWV1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4\DRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MkWyOkDPxE1? MXjTRW5ITVJ?
human CP66-MEL cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGfWNWxKdmirYnn0bY9vKG:oIHj1cYFvKEOSNk[tUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57M{W1PUDPxE1? MkDBV2FPT0WU
human HAL-01 cell MnPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrHfYRKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjd7MUig{txO MY\TRW5ITVJ?
human RS4-11 cell  M3PZfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLsTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlcxPTd|IN88US=> MkLGV2FPT0WU
human RPMI-8226 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVf1b2R3UW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVgzOjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkiyN|c3KM7:TR?= NHm1cY1USU6JRWK=
human NCI-H82 cell M2r5PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmnXTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45QTNyNTFOwG0> M4nsSXNCVkeHUh?=
human NY cells M3vmfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHzWeJVKdmirYnn0bY9vKG:oIHj1cYFvKE6\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6yO|Y{PyEQvF2= NXHmdFlsW0GQR1XS
human MDA-MB-361 cell NFzDc2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR|MUW4JO69VQ>? Ml\xV2FPT0WU
human MOLT-4 cell NELqPHFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPVkyQTNizszN NV7N[2NZW0GQR1XS
human DU-4475 cell MnXXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVXJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA2PTZ3IN88US=> NFfOTnRUSU6JRWK=
human ESS-1 cell NUKxV4d7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yPVE4QSEQvF2= M1PUbHNCVkeHUh?=
human NCI-H1299 cell Mnv1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTNyM{Og{txO M3rNT3NCVkeHUh?=
human COLO-684 cell MmHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jLTGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV6MU[1JO69VQ>? M{DqSnNCVkeHUh?=
human MV-4-11 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTvTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OTF7OTFOwG0> MkPoV2FPT0WU
human D-542MG cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnrRTY5pcWKrdHnvckBw\iCqdX3hckBFNTV2Ml3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{QTJ5MjFOwG0> MWfTRW5ITVJ?
human A4-Fuk cell M1rY[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJGE1NU[3azDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFM3PjJizszN M3LMWHNCVkeHUh?=
human HL-60 cell NXTxWWgxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlTDTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVIzOTJizszN NWfGflFQW0GQR1XS
human NCI-H526 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1PMN2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV7OECxJO69VQ>? MoXpV2FPT0WU
human L-363 cell NG\hN3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWPFcIpJUW6qaXLpeIlwdiCxZjDoeY1idiCOLUO2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPzl{NUKg{txO MlKzV2FPT0WU
human A388 cell NFTrTHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn7MTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64NFM5PCEQvF2= NIPnW29USU6JRWK=
human MS-1 M1nJOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWPsU5B5UW6qaXLpeIlwdiCxZjDoeY1idiCPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45OzR4NTFOwG0> NVqxdG9GW0GQR1XS
human JAR cell NWe4PIpVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn3STY5pcWKrdHnvckBw\iCqdX3hckBLSVJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki0PVI{KM7:TR?= NGnmTpBUSU6JRWK=
human TI-73 cell M3zkfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGexeYFKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4xPjJ{IN88US=> NHz3UYJUSU6JRWK=
human CTB-1 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLoT2lKdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4yPzh{NTFOwG0> NVzsV2RVW0GQR1XS
human SK-NEP-1 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1jyU2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5|MEO4JO69VQ>? M2HwfHNCVkeHUh?=
human HT-29 cell NXnHdmg3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLjTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzMlkyOTFizszN M{PNW3NCVkeHUh?=
human NCI-H1092 cell NYPYeHFpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1XIeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNFkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTRwM{G4JO69VQ>? MWrTRW5ITVJ?
human KMOE-2 cell NE[0em9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGtOV0VvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlYyPzhizszN NEfQXYNUSU6JRWK=
human EM-2 cell MmfIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jiUmlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlI5PDFizszN NFT3b|FUSU6JRWK=
human RT-112 cell NITuTVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV3SUGJYUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS5|OUi0JO69VQ>? NH3BS2JUSU6JRWK=
human DB cell M{TjPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXnJcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTVwOEWxN{DPxE1? MmW1V2FPT0WU
human NCI-H1770 cell MoDsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoDxTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3O|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? MYPTRW5ITVJ?
human CAL-54 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYDhWY5YUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPi55MzFOwG0> NWTI[pYxW0GQR1XS
human NB14 cell NFmyZXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNz62N|k2KM7:TR?= NWjF[HJkW0GQR1XS
human RPMI-7951 cell NUTyTY1uT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvN{m1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6NjF5OEOg{txO NETkVoxUSU6JRWK=
human T47D cell NIXMTndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmX3TY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlI1OyEQvF2= M3K2bnNCVkeHUh?=
human A549 cell NX;0XYYxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGrnVY1KdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zQDFzIN88US=> Mo[4V2FPT0WU
human A2780 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHTOR4tKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDJ{NTFOwG0> Mn\wV2FPT0WU
human SK-MEL-24 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2T5U2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwMEOxNUDPxE1? M1XCbHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID